ASTRAZENECA PLC

Explore how AstraZeneca’s AI‑driven discovery, Ultomiris’s Phase III breakthrough, and patient‑engagement strategies reshape market access and boost shareholder value.

Shares of AstraZeneca dipped in London, but the company’s mixed performance hinges on strong clinical data—especially SERENA‑6 results—highlighting its oncology pipeline’s potential, making investors watch closely for regulatory moves that could res…

FDA extends AstraZeneca’s camizestrant review, boosting its chance in advanced breast‑cancer treatment with ctDNA data, value‑based pricing, and global rollout plans.

AZN’s new peri‑operative immunotherapy for bladder and stomach cancers shows real survival gains, yet market success hinges on safety, pricing, and regulatory speed.

Discover how AstraZeneca’s efzimfotase alfa achieved breakthrough pediatric results in phase‑III trials for hypophosphatasia, its market‑access strategy, and future growth potential.

Explore how the Taltz + Zepbound combo boosts Psoriatic Arthritis outcomes and drives higher payer value with dual‑indication strategy and outcome‑based reimbursement.

Explore how AstraZeneca’s €260bn market cap and groundbreaking therapeutics, from Tagraxofusp to PulmoVax, shape FTSE 100 dynamics and healthcare budgets.

Explore how AstraZeneca’s Koselugo approval and German vaccine liability case shape its rare‑disease strategy and financial outlook.

Explore how AstraZeneca’s Q4 2025 earnings reveal a sharp rise in profit driven by oncology sales, a £3.5 bn pipeline push, and a 12 % dividend hike, setting a cautious 2026 outlook amid patent and regulatory challenges.

Explore how AstraZeneca’s earnings, R&D pipeline, and market‑access strategies shape its valuation and future growth potential.